TTNP.OB: Titan Pharmaceuticals Inc. Twitter

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 1, 9:56 AM Titan Pharmaceuticals (TTNP.OB -75.9%) loses more than three quarters of its market value after the FDA rejects its experimental opioid addiction treatment Probuphine. The company says it is "extremely surprised and disappointed" — shareholders likely feel the same. (See SA contributor Brian Wilson's opinion piece for more) 2 Comments [Healthcare, On the Move]
Monday, March 25, 4:40 PM Titan Pharmaceuticals (TTNP.OB +7.8%) extends gains Monday after rising more than 30% Friday on news the FDA has recommended approval of the company's opioid addiction drug Probuphine. Investors however, are no doubt still stinging from the ~40% dive the stock took last Tuesday. Comment! [Healthcare, On the Move]
Friday, March 22, 12:11 PM Shares of Titan Pharmaceuticals (TTNP.OB +35%) rise dramatically after the company says the FDA recommends approval for its opioid addiction treatment drug Probuphine. The terms of a licensing agreement announced last year indicate Titan will receive $50M from its commercialization partner Braeburn Pharmaceuticals upon FDA approval. 2 Comments [Healthcare, On the Move]
Tuesday, March 19, 9:34 AM Titan Pharmaceuticals' (TTNP.OB) Probuphine treatment for addiction to heroin and opioid painkillers has shown to be more effective than a placebo, but the data suggests that the dosages given might need to be higher, say FDA staff, who also raise safety concerns. The comments come ahead of a review on Thursday by an advisory panel about whether to recommend of approval for Probuphine. 7 Comments [Healthcare]

TTNP.OB Titan Pharmaceuticals Inc.

TTNP.OB

Titan Pharmaceuticals Inc.